Metabolic reprogramming of myeloid-derived suppressor cells (MDSC) in cancer

MDSC undergo metabolic reprogramming in the tumor resulting in an increased fatty acid β oxidation that supports their immunosuppressive functions. Fatty acid oxidation inhibitors, used to treat coronary disease, significantly delayed tumor growth and had a significantly increased antitumor effect w...

Full description

Saved in:
Bibliographic Details
Published in:Oncoimmunology 2016-08, Vol.5 (8), p.e1200771-e1200771
Main Authors: Al-Khami, Amir A., Rodriguez, Paulo C., Ochoa, Augusto C.
Format: Article
Language:English
Subjects:
Author's View
Cancer
Immunometabolism
MDSC
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c520t-10510e20322089799aac3e6b2886a16aaad87cfd4273cb9855600f81cebd2bb23
cites cdi_FETCH-LOGICAL-c520t-10510e20322089799aac3e6b2886a16aaad87cfd4273cb9855600f81cebd2bb23
container_end_page e1200771
container_issue 8
container_start_page e1200771
container_title Oncoimmunology
container_volume 5
creator Al-Khami, Amir A.
Rodriguez, Paulo C.
Ochoa, Augusto C.
description MDSC undergo metabolic reprogramming in the tumor resulting in an increased fatty acid β oxidation that supports their immunosuppressive functions. Fatty acid oxidation inhibitors, used to treat coronary disease, significantly delayed tumor growth and had a significantly increased antitumor effect when combined with adoptive cell therapy or low dose chemotherapy.
doi_str_mv 10.1080/2162402X.2016.1200771
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1819429123</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1819429123</sourcerecordid><originalsourceid>FETCH-LOGICAL-c520t-10510e20322089799aac3e6b2886a16aaad87cfd4273cb9855600f81cebd2bb23</originalsourceid><addsrcrecordid>eNp9UU1v2zAMFYYNa9H1J3TwsTs4I-VYti7DhnQfBVL00BboTZBlOtNgWx7ltMi_n42kwXaZLhTIx0fyPSEuEBYIJXyUqOQS5ONCAqoFSoCiwFfidM6nc-H18Y94Is5j_AXTU5CrTL8VJ7JQUoLSp2J9Q6OtQutdwjRw2LDtOt9vktAk3Y7a4Ou0JvZPVCdxOwxMMQZOHLVtTC5vru5WHxLfJ872jvideNPYNtL5IZ6Jh29f71c_0vXt9-vVl3XqcgljipAjkIRs2qHUhdbWuoxUJctSWVTW2rosXFMvZZG5Spd5rgCaEh1VtawqmZ2JT3veYVt1VDvqR7atGdh3lncmWG_-rfT-p9mEJ5NPQukcJ4LLAwGH31uKo-l8nG-yPYVtNFiiXkqNMpug-R7qOMTI1BzHIJjZDPNihpnNMAczpr73f-947HqRfgJ83gN83wTu7HPgtjaj3bWBG5709NFk_5_xB9t3mUM</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1819429123</pqid></control><display><type>article</type><title>Metabolic reprogramming of myeloid-derived suppressor cells (MDSC) in cancer</title><source>Open Access: PubMed Central</source><creator>Al-Khami, Amir A. ; Rodriguez, Paulo C. ; Ochoa, Augusto C.</creator><creatorcontrib>Al-Khami, Amir A. ; Rodriguez, Paulo C. ; Ochoa, Augusto C.</creatorcontrib><description>MDSC undergo metabolic reprogramming in the tumor resulting in an increased fatty acid β oxidation that supports their immunosuppressive functions. Fatty acid oxidation inhibitors, used to treat coronary disease, significantly delayed tumor growth and had a significantly increased antitumor effect when combined with adoptive cell therapy or low dose chemotherapy.</description><identifier>ISSN: 2162-4011</identifier><identifier>ISSN: 2162-402X</identifier><identifier>EISSN: 2162-402X</identifier><identifier>DOI: 10.1080/2162402X.2016.1200771</identifier><identifier>PMID: 27622069</identifier><language>eng</language><publisher>United States: Taylor &amp; Francis</publisher><subject>Author's View ; Cancer ; Immunometabolism ; MDSC</subject><ispartof>Oncoimmunology, 2016-08, Vol.5 (8), p.e1200771-e1200771</ispartof><rights>2016 Taylor &amp; Francis Group, LLC 2016</rights><rights>2016 Taylor &amp; Francis Group, LLC 2016 Taylor &amp; Francis Group, LLC</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c520t-10510e20322089799aac3e6b2886a16aaad87cfd4273cb9855600f81cebd2bb23</citedby><cites>FETCH-LOGICAL-c520t-10510e20322089799aac3e6b2886a16aaad87cfd4273cb9855600f81cebd2bb23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5007951/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5007951/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27622069$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Al-Khami, Amir A.</creatorcontrib><creatorcontrib>Rodriguez, Paulo C.</creatorcontrib><creatorcontrib>Ochoa, Augusto C.</creatorcontrib><title>Metabolic reprogramming of myeloid-derived suppressor cells (MDSC) in cancer</title><title>Oncoimmunology</title><addtitle>Oncoimmunology</addtitle><description>MDSC undergo metabolic reprogramming in the tumor resulting in an increased fatty acid β oxidation that supports their immunosuppressive functions. Fatty acid oxidation inhibitors, used to treat coronary disease, significantly delayed tumor growth and had a significantly increased antitumor effect when combined with adoptive cell therapy or low dose chemotherapy.</description><subject>Author's View</subject><subject>Cancer</subject><subject>Immunometabolism</subject><subject>MDSC</subject><issn>2162-4011</issn><issn>2162-402X</issn><issn>2162-402X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNp9UU1v2zAMFYYNa9H1J3TwsTs4I-VYti7DhnQfBVL00BboTZBlOtNgWx7ltMi_n42kwXaZLhTIx0fyPSEuEBYIJXyUqOQS5ONCAqoFSoCiwFfidM6nc-H18Y94Is5j_AXTU5CrTL8VJ7JQUoLSp2J9Q6OtQutdwjRw2LDtOt9vktAk3Y7a4Ou0JvZPVCdxOwxMMQZOHLVtTC5vru5WHxLfJ872jvideNPYNtL5IZ6Jh29f71c_0vXt9-vVl3XqcgljipAjkIRs2qHUhdbWuoxUJctSWVTW2rosXFMvZZG5Spd5rgCaEh1VtawqmZ2JT3veYVt1VDvqR7atGdh3lncmWG_-rfT-p9mEJ5NPQukcJ4LLAwGH31uKo-l8nG-yPYVtNFiiXkqNMpug-R7qOMTI1BzHIJjZDPNihpnNMAczpr73f-947HqRfgJ83gN83wTu7HPgtjaj3bWBG5709NFk_5_xB9t3mUM</recordid><startdate>20160802</startdate><enddate>20160802</enddate><creator>Al-Khami, Amir A.</creator><creator>Rodriguez, Paulo C.</creator><creator>Ochoa, Augusto C.</creator><general>Taylor &amp; Francis</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20160802</creationdate><title>Metabolic reprogramming of myeloid-derived suppressor cells (MDSC) in cancer</title><author>Al-Khami, Amir A. ; Rodriguez, Paulo C. ; Ochoa, Augusto C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c520t-10510e20322089799aac3e6b2886a16aaad87cfd4273cb9855600f81cebd2bb23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Author's View</topic><topic>Cancer</topic><topic>Immunometabolism</topic><topic>MDSC</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Al-Khami, Amir A.</creatorcontrib><creatorcontrib>Rodriguez, Paulo C.</creatorcontrib><creatorcontrib>Ochoa, Augusto C.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Oncoimmunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Al-Khami, Amir A.</au><au>Rodriguez, Paulo C.</au><au>Ochoa, Augusto C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Metabolic reprogramming of myeloid-derived suppressor cells (MDSC) in cancer</atitle><jtitle>Oncoimmunology</jtitle><addtitle>Oncoimmunology</addtitle><date>2016-08-02</date><risdate>2016</risdate><volume>5</volume><issue>8</issue><spage>e1200771</spage><epage>e1200771</epage><pages>e1200771-e1200771</pages><issn>2162-4011</issn><issn>2162-402X</issn><eissn>2162-402X</eissn><abstract>MDSC undergo metabolic reprogramming in the tumor resulting in an increased fatty acid β oxidation that supports their immunosuppressive functions. Fatty acid oxidation inhibitors, used to treat coronary disease, significantly delayed tumor growth and had a significantly increased antitumor effect when combined with adoptive cell therapy or low dose chemotherapy.</abstract><cop>United States</cop><pub>Taylor &amp; Francis</pub><pmid>27622069</pmid><doi>10.1080/2162402X.2016.1200771</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2162-4011
ispartof Oncoimmunology, 2016-08, Vol.5 (8), p.e1200771-e1200771
issn 2162-4011
2162-402X
2162-402X
language eng
recordid cdi_proquest_miscellaneous_1819429123
source Open Access: PubMed Central
subjects Author's View
Cancer
Immunometabolism
MDSC
title Metabolic reprogramming of myeloid-derived suppressor cells (MDSC) in cancer
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T18%3A48%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Metabolic%20reprogramming%20of%20myeloid-derived%20suppressor%20cells%20(MDSC)%20in%20cancer&rft.jtitle=Oncoimmunology&rft.au=Al-Khami,%20Amir%20A.&rft.date=2016-08-02&rft.volume=5&rft.issue=8&rft.spage=e1200771&rft.epage=e1200771&rft.pages=e1200771-e1200771&rft.issn=2162-4011&rft.eissn=2162-402X&rft_id=info:doi/10.1080/2162402X.2016.1200771&rft_dat=%3Cproquest_pubme%3E1819429123%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c520t-10510e20322089799aac3e6b2886a16aaad87cfd4273cb9855600f81cebd2bb23%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1819429123&rft_id=info:pmid/27622069&rfr_iscdi=true